Two Sigma Advisers’s Avadel Pharmaceuticals AVDL Stock Holding History

Two Sigma Advisers’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-45,900	Closed	-$989K	–	209
2025 Q4	$989K	Buy	+45,900	New	+$891K	﹤0.01%	1484
2023 Q3	–	Sell	-124,500	Closed	-$2.05M	–	2387
2023 Q2	$2.05M	Buy	124,500 +18,800	+18%	+$244K	0.01%	1187
2023 Q1	$968K	Buy	105,700 +12,600	+14%	+$104K	﹤0.01%	1648
2022 Q4	$667K	Sell	93,100 -2,700	-3%	-$18.9K	﹤0.01%	1763
2022 Q3	$480K	Buy	95,800 +66,300	+225%	+$365K	﹤0.01%	1856
2022 Q2	$72K	Buy	+29,500	New	+$121K	﹤0.01%	2431

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Two Sigma Advisers's AVDL Position: Q1 2026 in Review

Two Sigma Advisers sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 45,900 shares — an estimated $989K sold.

Two Sigma Advisers first reported a position in AVDL in Q2 2022 and held it in 6 quarters. The position peaked at $2.05M in Q2 2023. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Two Sigma Advisers reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 45,900 Avadel Pharmaceuticals shares in Q1 2026, an estimated $989K.
Two Sigma Advisers first reported a position in Avadel Pharmaceuticals in Q2 2022 and held it in 6 quarters.
Two Sigma Advisers's Avadel Pharmaceuticals position peaked at $2.05M in Q2 2023.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.